Kinase Genotyping of Gastro Intestinal Stomach Tumors (GISTs) From Patients Enrolled in Pfizer A6181112 Phase IIIb Trial

Back to Search
Print
Bookmark Trial

NCT00640692

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Gastrointestinal Neoplasm
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-80 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients enrolled in Pfizer A6181112

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patients who do not consent for analysis of their tumor in this companion study

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Gastrointestinal NeoplasmKinase Genotyping of Gastro Intestinal Stomach Tumors (GISTs) From Patients Enrolled in Pfizer A6181112 Phase IIIb Trial
NCT00640692
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Gastrointestinal NeoplasmA Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248
NCT00094029
  1. Duarte, California
  2. Pasadena, California
  3. San Francisco, California
  4. Santa Monica, California
  5. Washington, District of Columbia
  6. Gainesville, Florida
  7. Gainsville, Florida
  8. Miami, Florida
  9. Tampa, Florida
  10. Niles, Illinois
  11. Park Ridge, Illinois
  12. Boston, Massachusetts
  13. New Bedford, Massachusetts
  14. Detroit, Michigan
  15. Detroit, Michigan
  16. Farmington Hills, Michigan
  17. Minneapolis, Minnesota
  18. Rochester, Minnesota
  19. Creve Coeur, Missouri
  20. St. Louis, Missouri
  21. St. Louis, Missouri
  22. Bronx, New York
  23. Buffalo, New York
  24. New York, New York
  25. New York, New York
  26. Durham, North Carolina
  27. Portland, Oregon
  28. Portland, Oregon
  29. Dallas, Texas
  30. Seattle, Washington
  31. Seattle, Washington
  32. Madison, Wisconsin
  33. Burnos Aires,
  34. Camperdown, New South Wales
  35. Randwick, New South Wales
  36. Auchenflower, Queensland
  37. Bedford Park, South Australia
  38. East Melbourne, Victoria
  39. Nedlands, Western Australia
  40. Ashford SA,
  41. Auchenflower QLD,
  42. Graz,
  43. Wien,
  44. Brussels,
  45. Leuven,
  46. Calgary, Alberta
  47. Vancouver, British Columbia
  48. Winnipeg, Manitoba
  49. St. John's, Newfoundland and Labrador
  50. Toronto, Ontario
  51. Montreal, Quebec
  52. Santiago, RM
  53. Bogota, Cundinamarca
  54. Brno,
  55. Praha 5,
  56. Aarhus C,
  57. Herlev,
  58. Helsinki,
  59. Bordeaux Cedex,
  60. Lyon,
  61. Marseille,
  62. Berlin,
  63. Duesseldorf,
  64. Koeln,
  65. Muenchen,
  66. Thessaloniki,
  67. Happy Valley,
  68. Hong Kong,
  69. Budapest,
  70. New Delhi, Delhi
  71. Mumbai, Maharashtra
  72. Vellore, Tamil Nadu
  73. Tel Hashomer,
  74. Tel-Aviv,
  75. Aviano (PN),
  76. Aviano, PN,
  77. Bologna,
  78. Candiolo (TO),
  79. Genova,
  80. Milano,
  81. Milano,
  82. Milano,
  83. Torino,
  84. Seoul,
  85. Seoul,
  86. Mexico, DF
  87. Guadalajara, Jalisco
  88. Groningen, Gr
  89. Leiden,
  90. Oslo,
  91. Warszawa,
  92. Singapore,
  93. Singapore,
  94. Bratislava,
  95. Oviedo, Asturias
  96. L'Hospitalet de Llobregat, Barcelona
  97. Barcelona,
  98. Madrid,
  99. Sevilla,
  100. Valencia,
  101. Göteborg,
  102. Lausanne,
  103. Kaohsiung Hsien,
  104. Taipei,
  105. Taipei,
  106. Taipei,
  107. Ratchatawi, Bangkok
  108. Bangkok,
  109. Ankara,
  110. Inciralti / IZMIR,
  111. Istanbul,
  112. Leeds, England
  113. London,
  114. London,
  115. Manchester,
  116. Newcastle upon Tyne,
  117. Newcastle-Upon-Tyne,
  118. Caracas, Distrito Capital
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Kinase Genotyping of Gastro Intestinal Stomach Tumors (GISTs) From Patients Enrolled in Pfizer A6181112 Phase IIIb Trial
Official Title Kinase Genotyping of Gastrointestinal Stromal Tumors (GIST) From Patients Enrolled in the A6181112 Phase IIIb Trial at Participating U.S. and Ex-U.S. Medical Centers
Brief Summary The purpose of this study is to determine the genetic makeup of gastro intestinal stomach tumors (GISTs) from patients enrolled in the A6181112 phase IIIb trial. Tumor samples will be screened for mutations and this information will be used to determine whether the progression-free survival of patients being treated with the cancer medication sunitinib is related to the underlying genotype of their GIST.
Detailed Description In this companion study, we will analyze the genomic DNA from the GIST tumor specimens of patients enrolled in the in the A6181112 phase IIIb trial at participating U.S. and ex-U.S. medical centers. Specifically, GIST samples will be screened for mutations in KIT gene exons 9, 11, 13 and 17, and PDGFRA gene exons 12, 14 and 18, to determine the primary kinase genotype. Subset analyses will be performed and compared with the overall PFS rates observed in patients with primary and secondary imatinib resistance. Based on data from a previous phase I/II trial, our hypothesis is that patients with either primary or secondary imatinib resistance having a KIT exon 9-mutant or WT GIST will have a longer PFS when treated with sunitinib than patients with exon 11-mutant GIST. We further hypothesize that this difference will be observed among patients treated with high-dose imatinib.
Study Type Observational
Study Design Observational Model: Case-Control
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples With DNA
Description:
Genomic DNA from tumor samples
Sampling Method Non-Probability Sample
Study Population Patients enrolled in Pfizer A6181112
Condition Gastrointestinal Neoplasm
Intervention Not Provided
Study Groups/Cohorts
  • 1
  • 2
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Withdrawn
Actual Enrollment
 (submitted: October 31, 2019)		0
Original Estimated Enrollment
 (submitted: March 20, 2008)		120
Estimated Study Completion Date April 2011
Estimated Primary Completion Date September 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Patients enrolled in Pfizer A6181112

Exclusion Criteria:

  • Patients who do not consent for analysis of their tumor in this companion study
Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries United States
 
Administrative Information
NCT Number NCT00640692
Other Study ID Numbers Pfizer GIST Genotyping Study
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Oregon Health and Science University
Study Sponsor Oregon Health and Science University
Collaborators Pfizer
Investigators
Principal Investigator:Christopher L Corless, MD, PhDOregon Health and Science University
PRS Account Oregon Health and Science University
Verification Date October 2019